Transcription profiling by array of human breast cancer tumors following anastrozole treatment for 2 and 16 weeks

Analysis of breast cancer tumors following anastrozole treatment for 2 weeks and 16 weeks. The aromatase inhibitor anastrozole is an anti-estrogen drug used to treat postmenopausal women with breast cancer. Data provide insight into the molecular mechanism of action of anastrozole on hypoxia and proliferation metagenes. Core-cut tumor biopsies were collected from 81 postmenopausal women with stage I to IIIB ER+ early breast cancer before and after 2 weeks of anastrozole treatment. Further tumor biopsies were obtained from 20 of these patients after 16 weeks of anastrozole treatment prior to surgery